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Running head: Asymmetrical N4,N9-Diacyl Spermines are Efficient siRNA Vectors 
ABSTRACT: It is important to obtain structure-activity relationship (SAR) data across cationic 
lipids for the self-assembly and non-viral intracellular delivery of siRNA. The aims of this work 
are to carry out a SAR study on the efficiency of asymmetrical N4,N9-diacyl spermines in siRNA 
delivery and EGFP reporter gene silencing, with comparisons to selected mixtures composed of 
symmetrical N4,N9-diacyl spermines. Another important aim of these studies is to quantify the 
changes in cell viability, assayed with alamarBlue, as a function of lipid structure. Therefore, we 
have designed, synthesized, purified, and assayed novel cationic lipids that are asymmetrical 
lipopolyamines based on spermine. Flow cytometry and fluorescence microscopy in an EGFP 
stably transfected HeLa cell line, measuring both delivery of fluorescently tagged siRNAs and 
silencing the EGFP signal, allowed quantitation of the differences between asymmetrical cationic 
lipids, mixtures of their symmetrical counterparts, and comparison with commercial non-viral 
delivery agents. Intracellular delivery of siRNA and gene silencing by siRNA differ with 
different hydrophobic domains. In these asymmetrical N4,N9-diacyl spermines, lipids that 
enhance siRNA uptake do not necessarily enhance siRNA-induced inhibition of gene expression: 
C18 and longer saturated chains promote uptake, while more unsaturated C18 chains promote 
gene silencing. These properties are efficiently demonstrated in a new non-toxic cationic lipid 
siRNA vector, N4-linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) which is also 
shown to be comparable with or superior to TransIT-TKO and Lipofectamine 2000. 
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INTRODUCTION 
RNA interference (RNAi) was first noticed in petunia flowers which showed reduced 
pigmentation on the introduction of exogenous genes that were meant to increase pigmentation.1, 
2 Fire, Mello, and co-workers reported the reduction or inhibition of gene expression of a specific 
gene in Caenorhabditis elegans by means of dsRNA homologous to the targeted gene.3 In 2001, 
gene silencing in mammalian cells mediated by 21 nucleotide dsRNA homologous in sequence to 
the target gene was reported.4 Post-transcriptional gene silencing by short or small dsRNA, short 
interfering RNA (siRNA), typically 21-25 nucleotides in length, is mediated through the RNA-
induced silencing complex (RISC) in the cytoplasm. The RISC is comprised of proteins and the 
anti-sense strand of the siRNA. The key protein that has endoribonuclease activity is one of the 
Argonaute family of evolutionarily-conserved proteins (e.g. human Argonaute hAgo2)5 that are 
essential for development and differentiation, and in most plants and animals defend cells against 
viral infection. Sequence specific gene silencing is by degradation of mRNA that has a 
complementary sequence to the anti-sense siRNA strand present in the RISC complex.5, 6 
siRNA continues to gain popularity in functional genomics studies and as a potential 
therapeutic that can target many diseases ranging from age-related macular degeneration to 
different types of cancer and viral infections.7-9 Due to the highly negatively charged nature of the 
siRNA phosphate backbone, and due to its susceptibility to degradation by exo- and endo­
nucleases,10 a carrier (vector) is required to ensure successful intracellular siRNA delivery to 
target cells.11, 12 Since being introduced as non-viral gene delivery vectors in 1987 by Felgner and 
co-workers,13 cationic lipids have been widely studied as non-viral gene and siRNA vectors.14-16 
The majority of phospholipids in mammalian cell membranes are acylated with two 
different fatty acids at the sn-1 and sn-2 positions of the glycerol 3-phosphate.17-21 We have 
designed and synthesized various diacyl derivatives of spermine, a naturally occurring 
polyamine. These diacyl substituents, using either the same or two different fatty acids acylated 
to either positions N4 and N9, or N1 and N12, of spermine were then characterized and evaluated in 
vitro as non-viral vectors for the delivery of plasmid DNA (pDNA) and scrambled fluorescently 
labeled siRNA.22-26 In this work, we report the design and synthesis of seven new N4,N9­
diacylated asymmetrical spermine derivatives, asymmetrical in that they contain two different 
fatty acid chains, varying in length (from C18 to C24) and/or in their oxidation state. These novel 
asymmetrical polyamine amides are structurally similar to the naturally occurring diacyl lipids 
that form lipid cellular membranes.17-21 Using the two positive charges from the terminal primary 
amino groups, they are rationally designed to neutralize polynucleotides (e.g. siRNA) by titration 
and without any pre-formulation of liposomes. This titration occurs by the simple mixing of 
cationic lipids with polyanionic cargoes enabling self-assembly of lipoplex nanoparticles.22 The 
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target molecules are also designed to be efficient in coating the siRNA cargo with a protective 
lipid against serum RNase and therefore to be efficient in siRNA mediated gene silencing. We 
have reported the use in siRNA delivery of long and very long chains symmetrically substituted 
on spermine,23 but prior to our studies, there are no structure-activity relationship (SAR) data on 
asymmetrical spermine conjugates in gene silencing.27  
The synthesized spermine conjugates were homogeneous and characterized by NMR, 
high-resolution mass spectrometry (HRMS), and DLS. Their -potentials were also measured. 
They were then evaluated as non-viral siRNA delivery vectors and compared with commercially 
available siRNA delivery systems. To this end, we made use of a HeLa cell line that stably 
expresses the enhanced green fluorescent protein (EGFP) as a target for gene silencing and 
measured the efficiency of siRNA delivery and the associated reduction of EGFP expression. In 
the same system, we also investigated the difference between transfection with lipoplexes of the 
asymmetrical spermine conjugates (e.g. N4-linoleoyl-N9-oleoyl spermine), and transfection with 
lipoplexes of mixtures of their counterpart symmetrical spermine derivatives (e.g. N4,N9-
dilinoleoyl and N4,N9-dioleoyl). Others have also reported gene silencing studies on a comparable 
HeLa cell line,28, 29 on human embryonic kidney 293T cells stably expressing GFP,30 and on 
human embryonic retinoblast cells (911 cells) stably expressing luciferase.31  
 
MATERIAL AND METHODS 
 
 Materials. Chemicals were purchased as follows:  N-carbethoxyphthalimide, 
dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP), fatty acids, fatty acyl 
chlorides, hydrazine monohydrate, spermine, and triethylamine (TEA) from Sigma-Aldrich 
(Gillingham, UK); Mowiol (polyvinyl alcohol) from Calbiochem (Nottingham, UK); TransIT-
TKO from Mirus (Cambridge, UK); alamarBlue®, Alexa Fluor® 555-conjugated wheat germ 
agglutinin (WGA), Lipofectamine 2000, and RiboGreen, from Invitrogen Ltd, (Paisley, 
Scotland). All solvents were purchased from Fisher Scientific (Loughborough, UK). Anhydrous 
dichloromethane (DCM) was distilled from calcium hydride. Anhydrous tetrahydrofuran (THF) 
was distilled from sodium benzophenone ketyl. 
Cell culture materials were purchased from Life Technologies (Invitrogen Ltd, Paisley, 
Scotland) and GIBCO (Paisley, Scotland) except fetal calf serum (FCS, PAA Laboratories, 
Teddington, UK), G418 (Geneticin, an aminoglycoside antibiotic similar in structure to 
gentamicin B1) (Sigma, Gillingham, UK), and PBS (Oxoid, Basingstoke, UK). The water used to 
prepare solutions was from a MilliQ purification system (Millipore, Bedford, MA, USA). HeLa 
cells were routinely passaged by trypsinization using 0.25% trypsin. 
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 General Methods. Glassware used in anhydrous conditions was heated for 16 h at 80 °C, 
assembled hot, filled with anhydrous nitrogen and allowed to cool to 20 °C before use. Thin layer 
chromatography (TLC) was performed using aluminium-backed plates coated with Kieselgel 60 
F254 (Merck). Ninhydrin (0.2 g) in ethanol (100 mL) was used for detecting polyamines on TLC 
plates. Column chromatography was performed over flash silica gel 60 (35-75 μm; Prolabo-
Merck). NMR spectra were recorded as dilute solution in deuteriochloroform using a Bruker 
Avance III spectrometer operating at 400.1 MHz spectrometer for 1H and at 100.8 MHz for 13C. 
Chemical shifts values are recorded in parts per million (ppm) on the δ scale. Coupling constants 
(J) are absolute values (line separations) and recorded in Hz, assigned as s (singlet), m 
(multiplet), and t (triplet). 13C NMR assignments were aided by correlation spectroscopies; 
COSY, HMBC, HMQC spectra were all recorded using automated programmes. The high 
resolution (HR) time-of-flight (TOF) mass spectra (MS) were obtained on a Bruker Daltonics 
micrOTOF mass spectrometer using electrospray ionisation (ESI). All lipopolyamines were 
homogeneous by TLC and showed satisfactory HRMS data (positive ion mode reported as m/z 
and within 5 ppm). 
siRNAs. AllStars (scrambled) siRNA negative controls, both without a fluorescent tag 
(siNC) and tagged with Alexa Fluor® 647 (AF647) at the 3'-position (siNC-AF) were purchased 
from Qiagen (Crawley, UK) as was siRNA against EGFP labeled with Alexa Fluor® 647 
(siEGFP-AF) at the 3'-position of the sense strand. siEGFP-AF sequences are:   
Sense strand:  5'-GCAAGCUGACCCUGAAGUUCAUTT-3', 
Anti-sense strand:  5'-AUGAACUUCAGGGUCAGCUUGCCG-3', 
Target DNA sequence:  5'-CGGCAAGCTGACCCTGAAGTTCAT-3'. 
 
 Synthesis of Diacylated Spermines. 
 1,12-Diphthalimido-4,9-diazadodecane. 
 To a solution of 1,12-diamino-4,9-diazadodecane (spermine) (2.02 g, 10 mmol) in DCM 
(30 mL) N-carbethoxyphthalimide (4.38 g, 20 mmol) was added. The solution was stirred at 20 
°C for 3 h then evaporated to dryness in vacuo. The residue was purified over silica gel 
(DCM:MeOH 10:1 then 2:1 v/v) to afford the title compound (2.13 g, 46%). 1H NMR, 1.2-1.4 
(m, 4H, H6, H7), 1.4-1.7 (m, 6H, H2, H11, 2 x NH), 2.4-2.5 (m, 8H, H3, H5, H8, H10), 3.6 (m, 
4H, H1, H12), 7.5-7.7 (m, 8H, aromatic protons). 13C NMR, 27.1 (C6, C7), 28.2 (C2, C11), 35.5 
(C1, C12), 46.3 (C3, C5, C8, C10), 122.7 and 133.6 (aromatic carbons), 168.1 (C=O). HRMS, 
found (M+H)+ 463.2354, C26H31N4O4 requires (M+H)+ 463.2340. Often, for the synthesis of the 
following target molecules, the purification of 1,12-diphthalimido-4,9-diazadodecane can be 
skipped and the crude product taken on directly into the acylation. 
 
N4,N9-Dioleoyl-1,12-diamino-4,9-diazadodecane (DOS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (2.31 g, 5 mmol) in DCM (30 mL) 
and TEA (1.4 mL, 10 mmol) oleoyl chloride (3.3 mL, 10 mmol) was added. The solution was stirred 
for 18 h at 20 °C and then the solvent was evaporated to dryness in vacuo. The residue was reacted 
with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated 
under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo. The residue was 
purified over silica gel (DCM:MeOH 10:1 v/v then DCM:MeOH:NH4OH 10:5:1 v/v/v) to afford the 
title compound (1.46 g, 40% over two steps). 1H NMR, 0.8 (t, J = 7, 6H, H18'), 1.2-1.3 (m, 40H, H4'­
H7', H12'-H17'), 1.4-1.8 (m, 12H, H2, H6, H7, H11, H3'), 1.9-2.1 (m, 8H, H8', H11'), 2.1-2.3 (m, 
4H, H2'), 2.6-2.8 (m, 8H, H1, H12, 2 x NH2), 3.2-3.5 (m, 8H, H3, H5, H8, H10), 5.3-5.4 (m, 4H, 
H9', H10'). 13C NMR, 14.1 (C18'), 22.6-29.7 (C2, C6, C7, C11, C4'-C8', C11'-C17'), 31.9 (C3'), 33.1 
(C2'), 38.9-39.2 (C1, C12), 42.5-47.4 (C3, C5, C8, C10), 129.8 (C9', C10'), 172.9 (C1'). HRMS, 
found (M+H)+ 731.7162, C46H91N4O2 requires (M+H)+ 731.7137. 
N4,N9-Dierucoyl-1,12-diamino-4,9-diazadodecane (DEruS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (0.46 g, 1 mmol) in DCM (30 
mL) erucic acid (0.68 g, 2 mmol), DMAP (0.24 g, 2 mmol), and DCC (0.40 g, 2 mmol) were 
added. The solution was stirred at 20 °C for 18 h under an atmosphere of nitrogen, then filtered 
and the filtrate was evaporated to dryness in vacuo. The residue was reacted with hydrazine 
monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated under reflux for 
4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo. The residue was purified over 
silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 20:10:1 v/v/v) to afford the title 
compound (0.34 g, 40% over two steps). 1H NMR, 0.8 (t, J = 7, 6H, H22'), 1.1-1.3 (m, 60H, H4'­
H11', H16'-H21', 2 x NH2), 1.4-1.6 (m, 12H, H2, H6, H7, H11, H3'), 1.9 (m, 8H, H12'-H15'), 2.2­
2.4 (m, 4H, H2'), 2.5-2.7 (m, 4H, H1, H12), 3.2-3.6 (m, 8H, H3, H5, H8, H10), 5.2 (m, 4H, H13', 
H14'). 13C NMR, 14.0 (C22'), 22.6 (C21'), 25.1-32.8 (C2, C6, C7, C11, C3'-C12', C15'-C20'), 
33.1 (C2'), 39.2-39.4 (C1, C12), 42.6-47.4 (C3, C5, C8, C10), 129.8 (C13', C14'), 172.8-173.0 
(C1'). HRMS, found (M+H)+ 843.8364, C54H107N4O2 requires (M+H)+ 843.8389; found (M+Na)+ 
865.8194, C54H106N4O2Na requires (M+Na)+ 865.8208. 
N4,N9-Dilinoleoyl-1,12-diamino-4,9-diazadodecane (DLinS). 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (0.46 g, 1 mmol) in DCM (30 
mL) linoleic acid (0.56 g, 2 mmol), DMAP (0.24 g, 2 mmol), and DCC (0.40 g, 2 mmol) were 
added. The solution was stirred at 20 °C for 18 h under an atmosphere of nitrogen, then filtered 
and the filtrate was evaporated to dryness in vacuo. The residue was reacted with hydrazine 
monohydrate (2 mL) in a mixture of DCM (15 mL) and THF (15 mL) and heated under reflux for 
4 h, cooled to 20 °C, and then the solvent was evaporated in vacuo and the residue purified over 
silica gel (DCM/MeOH 10:1 v/v then DCM/MeOH/NH4OH 20:10:1 v/v/v) to afford the title 
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compound (0.29 g, 40% over two steps). 1H NMR, 0.8 (t, J = 7, 6H, H18'), 1.2-1.3 (m, 28H, H4'­
H7', H15'-H17'), 1.4-1.8 (m, 16H, H2, H6, H7, H11, H3', 2 x NH2), 1.9-2.0 (m, 8H, H8', H14'), 
2.0-2.3 (m, 4H, H2'), 2.5-2.7 (m, 8H, H1, H12, H11'), 3.2-3.4 (m, 8H, H3, H5, H8, H10), 5.2-5.3 
(m, 8H, H9', H10', H12', H13'). 13C NMR, 14.0 (C18'), 22.4 (C17'), 25.0-33.0 (C2, C6, C7, C11, 
C2'-C8', C11', C14'-C16'), 39.0-39.3 (C1, C12), 42.4-47.6 (C3, C5, C8, C10), 127.8-130.0 (C9', 
C10', C12', C13'), 172.7-173.0 (C1'). HRMS, found (M+H)+ 727.6851, C46H87N4O2 requires 
(M+H)+ 727.6824. 
1,12-Diphthalimido-N4-oleoyl-4,9-diazadodecane. 
To a solution of 1,12-diphthalimido-4,9-diazadodecane (2.31 g, 5 mmol) in DCM (30 
mL) oleic acid (1.6 mL, 5 mmol), DMAP (610 mg, 5 mmol), and DCC (1.03 g, 5 mmol) were 
added. The solution was stirred at 20 °C for 20 h then filtered and the filtrate was evaporated to 
dryness in vacuo. The residue was purified over silica gel (DCM:MeOH 20:1 v/v) to afford the 
title compound (1.34 g, 37%). 1H NMR, 0.9 (t, J = 7, 3H, H18'), 1.3 (m, 20H, H4'-H7', H12'­
H17'), 1.5-1.6 (m, 8H, H6, H7, H11, H3'), 1.9-2.0 (m, 7H, H2, H8', H11', 1 x NH), 2.1-2.3 (m, 
2H, H2'), 2.7-2.8 (m, 4H, H8, H10), 3.2-3.5 (m, 4H, H3, H5), 3.6-3.8 (m, 4H, H1, H12), 5.3 (m, 
2H, H9', H10'), 7.7-7.8 (m, 8H, aromatic). 13C NMR, 14.1 (C18'), 22.6 (C17'), 25.1-31.8 (C2, C6, 
C7, C11, C3'-C8', C11'-C16'), 33.1 (C2'), 35.3-35.9 (C1, C12), 45.2-50.6 (C3, C5, C8, C10), 
123.1-123.3 and 131.8-134.1 (aromatic carbons), 129.7-129.9 (C9', C10'), 168.2-168.4 (C=O 
phthalimide), 173.0 (C1'). HRMS, found (M+H)+ 727.4801, C44H63N4O5 requires (M+H)+ 
727.4793. 
N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS). 
To a solution of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane (0.72 g, 1 mmol) and 
TEA (0.14 mL, 1 mmol) in DCM (30 mL) linoleoyl chloride (0.33 mL, 1 mmol) was added. The 
solution was stirred at 20 °C for 18 h then the solvent was evaporated to dryness in vacuo. The 
residue was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF 
(15 mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in 
vacuo. The residue was purified over silica gel (DCM:MeOH 10:1 v/v then DCM:MeOH:NH4OH 
10:5:1 v/v/v) to afford the title compound (0.27 g, 37% over two steps). 1H NMR, 0.9 (t, J = 7, 
6H, H18', H18"), 1.2-1.4 (m, 34H, H4'-H7', H15'-H17', H4"-H7", H12"-H17"), 1.4-1.7 (m, 12H, 
H2, H6, H7, H11, H3', H3"), 1.8-2.0 (m, 12H, H8', H14', H8", H11", 2 x NH2), 2.0-2.3 (m, 4H, 
2', 2"), 2.6-2.8 (m, 6H, H1, H12, H11'), 3.2-3.4 (m, 8H, H3, H5, H8, H10), 5.3 (m, 6H, H9', H10', 
H12', H13', H9", H10"). 13C NMR, 14.0 (C18', C18"), 22.4 (C17', C17"), 25.0-26.8 (C2, C6, C7, 
C11, C11') , 27.1-27.2 (8', 14', 8", 11") , 29.1-29.6 (4'-7', 15'-17', 4"-7", 12"-17"), 30.9-32.9 (C3', 
C16', C3", C16"), 33.0 -36.7 (C2', C2"), 38.9-39.3 (C1, C12), 42.4-47.6 (C3, C5, C8, C10), 
127.8-130.0 (C9', C10', C12', C13', C9", C10"), 172.7-173.0 (C1', C1"). HRMS, found (M+H)+ 
729.6980, C46H89N4O2 requires (M+H)+ 729.6986. 
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N4-Oleoyl-N9-stearoyl-1,12-diamino-4,9-diazadodecane (OSS). 
To a solution of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane (0.72 g, 1 mmol) and 
TEA (0.14 mL, 1 mmol) in DCM (30 mL) stearoyl chloride (0.34 mL, 1 mmol) was added. The 
solution was stirred at 20 °C for 18 h then the solvent evaporated to dryness in vacuo. The 
residue was reacted with hydrazine monohydrate (2 mL) in a mixture of DCM (15 mL) and THF 
(15 mL) and heated under reflux for 4 h, cooled to 20 °C, and then the solvent was evaporated in 
vacuo. The residue was purified over silica gel (DCM:MeOH 10:1 v/v then DCM:MeOH:NH4OH 
10:5:1 v/v/v) to afford the title compound (0.31 g, 43% over two steps). 1H NMR, 0.8 (t, J = 7, 
6H, H18', H18"), 1.2-1.4 (m, 48H, H4'-H7', H12'-H17', H4"-H17"), 1.4-1.8 (m, 16H, H2, H6, H7, 
H11, H3', H3", 2 x NH2), 1.9-2.0 (m, 4H, H8', H11'), 2.1-2.3 (m, 4H, H2', H2"), 2.6-2.8 (m, 4H, 
H1, H12), 3.2–3.4 (m, 8H, H3, H5, H8, H10), 5.3 (m, 2H, H9’, H10’). 13C NMR, 14.3 (C18', 
C18"), 22.9 (C17', C17"), 25.4-29.6 (C2, C6, C7, C11, C4'-C8', C11'-C15', C4"-C15"), 31.4, 32.9 
(C3', C3"), 32.1 (C16', C16"), 33.3 (C2', C2"), 39.4 (C1, C12), 42.7-47.6 (C3, C5, C8, C10), 
130.0 (C9', C10'), 173.1 (C1', C1"). HRMS, found (M+Na)+ 755.7112, C46H92N4O2Na requires 
(M+Na)+ 755.7118. 
General Procedure for the synthesis of asymmetrical acyl spermine derivatives using 
DCC coupling. The required carboxylic acid (1 mmol), DMAP (122 mg, 1 mmol), and DCC (206 
mg, 1 mmol) were added to a solution of 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane (726 
mg, 1 mmol) in DCM (15 mL). The solution was stirred at 20 °C for 20 h then filtered and the 
filtrate was evaporated to dryness in vacuo. The residue was reacted with hydrazine monohydrate 
(2 mL) in a mixture of DCM (10 mL) and THF (10 mL) and heated under reflux for 4 h, cooled to 
20 °C, and then the solvent was evaporated in vacuo. The residue was purified over silica gel 
(DCM:MeOH 10:1 v/v then DCM:MeOH:NH4OH 100:10:1 v/v/v) to afford the title compound. 
N4-Arachidonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (AOS). 
According to the General Procedure, arachidonic acid (304 mg, 1 mmol) was reacted to 
afford the title compound (301 mg, 40% over two steps). 1H NMR, 0.9 (m, 6H, J = 7, H20', 
H18"), 1.2-1.8 (m, 42H, H2, H6, H7, H11, H3', H17'-H19', H3"-H7", H12"-H17", 2 x NH2), 2.0­
2.2 (m, 8H, H4', H16', H8", H11"), 2.2-2.4 (m, 4H, 2', 2"), 2.6-2.8 (m, 10H, H1, H12, H7', H10', 
H13'), 3.2-3.4 (m, 8H, H3, H5, H8, H10), 5.3-5.4 (m, 10H, H5', H6', H8', H9', H11', H12', H14', 
H15', H9", H10"). 13C NMR, 14.1 (C20', C18"), 22.5-22.6 (C19', C17"), 25.3-27.2 (C4', C7', 
C10', C13', C16', C8", C11"), 29.2-32.7 (C2, C6, C7, C11, C3', C17', C18', C3"-C7", C12"­
C16"), 33.1 (C2', C2"), 39.0-39.4 (C1, C12); 42.5-47.3 (C3, C5, C8, C10), 127.5-130.5 (C5', C6', 
C8', C9', C11', C12', C14', C15', C9", C10"), 172.6-172.8 (C1', C1"). HRMS, found (M+H)+ 
753.6982, C48H89N4O2 requires (M+H)+ 753.6980. 
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N4-Eicosenoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EicOS). 
According to the General Procedure, eicosenoic acid (310 mg, 1 mmol) was reacted to 
afford the title compound (273 mg, 36% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H20', H18"), 
1.2-1.3 (m, 44H, H4'-H9', H14'-H19', H4"-H7", H12"-H17"), 1.4-1.8 (m, 12H, H2, H6, H7, H11, 
H3', H3"), 2.0 (m, 8H, H10', H13', H8", H11"), 2.2-2.4 (m, 8H, H2', H2", 2 x NH2), 2.6-2.8 (m, 
4H, H1, H12), 3.2-3.45 (m, 8H, H3, H5, H8, H10), 5.3-5.4 (m, 4H, H11', H12', H9", H10"). 13C 
NMR, 14.1 (C20', C18"), 22.7 (C19', C17"), 25.1-32.6 (C2, C6, C7, C11, C3'-C10', C13'-C18', 
C3"-C8", C11"-C16"), 33.1 (C2', C2"), 38.8-39.4 (C1, C12), 42.5-47.5 (C3, C5, C8, C10), 129.8 
(C11', C12', C9", C10"), 172.9-173.4 (C1', C1"). HRMS, found (M+H)+ 759.7450, C48H95N4O2 
requires (M+H)+ 759.7455. 
N4-Erucoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EruOS). 
According to the General Procedure, erucic acid (339 mg, 1 mmol) was reacted to afford 
the title compound (268 mg, 34% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H22', H18"), 1.2­
1.4 (m, 48H, H4'-H11', H16'-H21', H4"-H7", H12"-H17"), 1.4-1.7 (m, 16H, H2, H6, H7, H11, 
H3', H3", 2 x NH2), 2.0 (m, 8H, H12', H15', H8", H11"), 2.3 (m, 4H, H2', H2"), 2.8 (m, 4H, H1, 
H12), 3.2-3.4 (m, 8H, H3, H5, H8, H10), 5.3 (m, 4H, H13', H14', H9", H10"). 13C NMR, 14.1 
(C22', C18"), 22.6 (C21', C17"), 25.1-27.2 (C2, C6, C7, C11, C12', C15', C8", C11"), 29.1-32.7 
(C3'-C11', C16'-C20', C3"-C7", C12"-C16"), 33.1 (C2', C2"), 39.1-39.4 (C1, C12), 42.4-47.3 
(C3, C5, C8, C10), 129.7-129.9 (C13', C14', C9", C10"), 172.8-173.0 (C1', C1"). HRMS, found 
(M+H)+ 787.7763, C50H99N4O2 requires (M+H)+ 787.7768. 
N4-Lignoceroyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LigOS). 
According to the General Procedure, lignoceric acid (369 mg, 1 mmol) was reacted to 
afford the title compound (310 mg, 38% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H24', H18"), 
1.2-1.4 (m, 64H H4'-H23', H4"-H7", H12"-H17", 2 x NH2), 1.4-1.7 (m, 12H, H2, H6, H7, H11, 
H3', H3"), 2.0 (m, 4H, H8", H11"), 2.2-2.3 (m, 4H, 4H, H2', H2"), 2.6-2.8 (m, 4H, H1, H12), 3.2­
3.4 (m, 8H, H3, H5, H8, H10), 5.3 (m, 2H, H9", H10"). 13C NMR, 14.1 (C24', C18"), 22.6 (C23', 
C17"), 25.1-27.2 (C2, C6, C7, C11, C8", C11"), 29.2-32.7 (3'-22', 3"-7", 12"-16"), 33.1 (C2', 
C2"), 39.2-39.4 (C1, C12), 42.5-47.3 (C3, C5, C8, C10), 129.7-129.9 (C9", C10"), 172.8-173.0 
(C1', C1"). HRMS, found (M+H)+ 817.8232, C52H105N4O2 requires (M+H)+ 817.8238. 
N4-Nervonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (NOS). 
According to the General Procedure, nervonic acid (367 mg, 1 mmol) was reacted to 
afford the title compound (302 mg, 37% over two steps). 1H NMR, 0.9 (t, J = 7, 6H, H24', H18"), 
1.2-1.4 (m, 52H, H4'-H13', H18'-H23', H4"-H7", H12"-H17"), 1.4-1.8 (m, 12H, H2, H6, H7, H11, 
H3', H3"), 2.0 (m, 8H, H14', H17', H8", H11"), 2.2-2.4 (m, 4H, H2', H2"), 2.6-2.8 (m, 4H, H1, 
H12), 3.2-3.4 (m, 12H, H3, H5, H8, H11, 2 x NH2), 5.3 (m, 4H, H15', H16', H9", H10"). 13C 
NMR, 14.1 (C24', C18"), 22.6 (C23', C17"), 25.5-27.2 (C2, C6, C7, C11, C14', C17', C8", C11"), 
8
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29.1-32.8 (C3'-C13', C18'-C22', C3"-C7", C12"-C16"), 33.1 (C2', C2"), 39.0-39.5 (C1, C12), 42.5-
47.6 (C3, C5, C8, C10), 129.8 (C15', C16', C9", C10"), 172.7-172.8 (C1', C1"). HRMS, found 
(M+H)+ 815.8076, C52H103N4O2 requires (M+H)+ 815.8081. 
 
HeLa cell line stably expressing EGFP (HeLa-EGFP). The HeLa cell line stably 
expressing the red-shifted enhanced variant of wild-type GFP (EGFP) used here as a reporter 
protein was obtained from the Cell Service at Cancer Research UK (CRUK, London Research 
Institute, Clare Hall Laboratories, South Mimms, London, UK) and was constructed by Dr Yilun 
Liu. Briefly, the centrin protein (CEN) was subcloned into the expression vector pEGFP-C1 
(Clontech, Cowley, UK), downstream of EGFP, under the control of the human CMV promoter. 
The plasmid was linearized and transfected into HeLa cells. Stably transfected cells were selected 
with G418 and maintained as a polyclonal cell line, cultivated in DMEM medium supplemented 
with 10% FCS, penicillin base (50 units/mL), streptomycin (50 g/mL), and G418 (500 g/mL) in 
order to prevent the progressive loss of pDNA occurring during cell cultivation. The percentage of 
EGFP positive cells was >80% as measured by flow cytometry (FACS) (data not shown) and 
regularly was verified prior to siRNA transfection experiments. 
Transfection Studies of HeLa Cells Stably Expressing EGFP. On the day of 
transfection, cells were trypsinized at a confluency of 80-90% and were seeded at a density of 
100,000 cells/well in 24-well plates. The lipoplexes were prepared by mixing the specified 
amounts of the transfection reagent in OptiMEM serum-free medium (50 L) with siRNA (15 
L, 1 M working solution) in OptiMEM serum-free medium. Lipofectamine 2000 (2 L/well) 
and TransIT-TKO (4 L/well) were used in accordance with the manufacturers’ instructions, 
both were used in the presence of 10% FCS. The solutions were vortex-mixed for 2-3 s, and 
added to wells containing DMEM (10% FCS and without G418), within 0.5 h of seeding, to 
make the final volume in each well 1 mL (siRNA final concentration 15 nM). The plates were 
then incubated for 48 h at 37 °C in 5% CO2. N/P ratios (defined as the ratio of cationic lipid 
ammonium ions to RNA phosphate anions) were calculated as:   
siRNAdsinphosphatesofnumbertotalsiRNAofmolesofnumber
lipidcationicofmolesofnumberPN



0.2/  
 
Flow Cytometry (FACS). For analysis of delivery and then reduction of expression of 
EGFP by flow cytometry (FACS), cells were trypsinized and resuspended in complete DMEM 
medium without phenol red. Cells were centrifuged (1,000 rpm Falcon 6/300 MSE, London, UK, 
for 5 min) then washed twice by resuspending in PBS containing 0.1% BSA, and then re-
centrifuged (1,000 rpm for 5 min). The collected cells were then resuspended in PBS and 
transferred to a flow cytometer tube (Becton Dickinson, UK). Cells were then analyzed (10,000 
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or 20,000 events) using a FACSCanto flow cytometer (Becton Dickinson, UK), equipped with an 
argon ion laser at 488 nm for excitation, a Long Pass (LP) filter at 502 nm, and a detector at 530 
nm (range +/-15 nm) for green fluorescence emission, and a helium/neon laser at 633 nm for 
excitation of Alexa Fluor 647 and a detector at 660 nm (range +/- 10 nm). EGFP expression was 
calculated as:   
100% 
cellscontrolofcefluorescenEGFP
cellsdtransfecteofcefluorescenEGFPEGFP  
 
siRNA delivery was evaluated (48 h post-transfection) by means of normalizing the 
geometric mean fluorescence of the Alexa Fluor 647 of each sample relative to the geometric 
mean fluorescence of Alexa Fluor 647-siRNA delivered by either of two standards (DOS or 
TransIT-TKO). 
Confocal Microscopic Cell Imaging. Cells were trypsinized at a confluency of 80-90%, 
seeded at a density of 65,000 cells/well in 24-well plates on round glass coverslips (12 mm in 
diameter) and grown for 24 h prior to transfection which was carried out as described above. At 
48 h post-transfection, the cell culture media were aspirated from each well and the cells were 
washed with PBS (3 x 0.5 mL). The cell membrane was then stained with Alexa Fluor 555-
conjugated WGA (5 µg/mL in Hank’s balanced salt solution without phenol red). The cells were 
incubated for 10 min in the dye working solution at 37 °C in 5% CO2 in the dark. The cells were 
then washed with PBS (3 x 0.5 mL) and finally fixed with 4% paraformaldehyde in PBS solution 
for 20 min at 20 °C in the dark. The coverslips were then removed from the wells, left to dry 
briefly in air, and then mounted on glass slides using Mowiol (polyvinyl alcohol) solution and 
left in the dark at 20 °C (18 h) to allow hardening of the mounting media. The cells were 
examined using a Carl Zeiss laser scanning microscope LSM 510 meta, with EGFP excitation 
488 nm, emission 505-550 nm (band pass filter), Alexa Fluor 555 excitation 543 nm, emission 
560-615 nm (band pass filter), and Alexa Fluor 647 excitation 633 nm, emission 657-753 nm 
(meta detector). 
Cell Viability Assay. HeLa cells were trypsinized at a confluency of 80-90% and seeded 
at a density of either 6,500 (transfection after 24 h) or 4,000 (transfection after 0.5 h) cells per 
well of 96-well plates. The transfection was carried out using the same protocol as transfecting 
the 24-well plates with the exception of reducing the amount of lipoplexes such that each well 
contains 1.5 pmol siRNA in a final volume of 100 L/well of DMEM containing 10% FCS. After 
incubation for 44 h at 37 °C in 5% CO2, alamarBlue (10 L) was added to each well. After 
incubation for 3.5 h at 37 °C in 5% CO2, the absorbance of each well was measured at 570 nm 
and 600 nm using a microplate-reader (VERSAmax), and the calculation of the amount of 
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alamarBlue reduced measured at 570 nm was carried out according to the standard protocol 
provided by the alamarBlue supplier (Invitrogen). Percentage viability was calculated as: 
100% 
cellscontrolofalamarBlueofreducedamount
cellssampleofalamarBlueofreducedamountviability  
 
Particle Size and -Potential Measurements. Lipoplexes were prepared by adding 
siRNA solution (75 L, 1 M in 10 mM HEPES buffer, pH 7.4) to HEPES (250 µL) containing 
the specified amount of cationic lipid followed by vortex mixing for 2-3 s. Samples were then 
diluted to a final volume of 3 mL with HEPES buffer and shaken for 10 s. DLS measurements 
were carried out using a Malvern Zetasizer Nano S90 with refractive index 1.59, viscosity 0.89 
cP, dielectric constant 79, at 25 °C with equilibrium time 3 min. Z-Average diameter in nm and 
-potential in mV were recorded as averages of three and six measurements respectively. 
siRNA Binding (RiboGreen Intercalation Assay). RiboGreen working solution was 
prepared by diluting RiboGreen stock solution 1 to 400 in TE buffer (10 mM Tris-HCl, 1 mM 
EDTA, pH 7.5 diluted 1 to 20 in RNase free water). RiboGreen working solution (40 μL) was 
added to each well of a 96-well plate (black bottom) containing free siRNA (1 pmol) or 
complexed with lipospermines in TE buffer at the lipid/siRNA ratios that showed the best 
reduction in EGFP expression. Each well contained a final volume of 120 µL. The fluorescence 
was measured (n = 6) using FLUOstar Optima Microplate Reader (BMG-LABTECH), ex = 480 
nm and em = 520 nm. The amount of siRNA available to interact with the lipid vector was 
calculated by subtracting the values of RiboGreen background fluorescence (RiboGreen without 
siRNA) from each measurement, and expressed as a percentage of the control that contained 
naked siRNA only, calculated as:   
100% 
siRNAnakedofcefluorescenRiboGreen
complexesofcefluorescenRiboGreensiRNAfree  
 
Statistical Analysis. All data are presented as mean + S.D. (n = 9). The mean values and 
S.D. were determined using MS Office Excel 2003. Statistical significance of differences 
between data was evaluated by Student’s unpaired two tailed t-test. A value of p < 0.05 was 
considered significant and p values were determined using GraphPad.  
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RESULTS 
 
1,12-Diphthalimido-4,9-diazadodecane 
 
 
N4,N9-Dioleoyl-1,12-diamino-4,9-diazadodecane (DOS) C18:1 9 and C18:1 9 
N
NNH2
NH2
O
O  
N4,N9-Dierucoyl-1,12-diamino-4,9-diazadodecane (DEruS) C22:1 13 and C22:1 13 
 
 
N4,N9-Dilinoleoyl-1,12-diamino-4,9-diazadodecane (DLinS) C18:2 9,12 and C18:2 9,12 
 
 
1,12-Diphthalimido-N4-oleoyl-4,9-diazadodecane 
N
N
N
N
H
O
O
O
O
O
 
N4-Arachidonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (AOS) C20:4 5,8,11,14 and C18:1 9 
NH2 N
N NH2
O
O  
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N4-Eicosenoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EicOS) C20:1 11 and C18:1 9 
O
N
NH2 N
NH2
O
 
 
N4-Erucoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (EruOS) C22:1 13 and C18:1 9 
NH2N
O
NNH2
O
 
 
N4-Lignoceroyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LigOS) C24:0 and C18:1 9 
O
N
NH2 N
NH2
O
 
 
N4-Linoleoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (LinOS) C18:2 9,12 and C18:1 9 
O
NH2 N
N NH2
O  
 
N4-Nervonoyl-N9-oleoyl-1,12-diamino-4,9-diazadodecane (NOS) C24:1 15 and C18:1 9 
N
NH2N
O
NH2
O
 
 
N4-Oleoyl-N9-stearoyl-1,12-diamino-4,9-diazadodecane (OSS) C18:1 9 and C18:0 
O
O
N
NNH 2
NH 2
 
Figure 1. Target asymmetrical and symmetrical N4,N9-diamides of spermine. 
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Spermine (1,12-diamino-4,9-diazadodecane or N,N′-bis(3-aminopropyl)-1,4-
diaminobutane) has two terminal primary amine groups at carbons 1 and 12, and two secondary 
amine groups with their nitrogen atoms numbered 4 and 9. In order to conjugate two different 
fatty acids at the N4 and N9 positions, first, the two terminal primary amines were protected with 
phthalimide, then one fatty acid (oleic, 18:1) was acylated on position N4 using oleic 
acid/DCC/DMAP to conjugate in a 1:1 stoichiometry with an oleoyl chain (Figure 1).32 The 
purified mono-acylated product, 1,12-diphthalimido-N4-oleoyl-4,9-diazadodecane, was then 
conjugated with the second long-chain fatty acid using DCC/DMAP. This method avoids using 
orthogonal protection of the primary and secondary amino groups with different protecting 
groups (e.g. phthalimide for the primary amines and then Boc for the secondary amines) and 
hence we obtained the target products in fewer reactions. Keeping one fatty acid chain constant 
as oleic acid (18:1), the free secondary amine group of 1,12-diphthalimido-N4-oleoyl-4,9-
diazadodecane was acylated with:  arachidonic (20:4), eicosenoic (20:1), erucic (22:1), lignoceric 
(24:0), linoleic (18:2), nervonic (24:1), and stearic (18:0) acids. Whilst all the other molecules are 
named with the oleoyl group at N9, N4-oleoyl-N9-stearoyl-1,12-diamino-4,9-diazadodecane (OSS) 
is named as such to reflect the alphabetical order of oleoyl-stearoyl (IUPAC nomenclature), but 
this does not alter the relative structures within the diacylated-spermine series. Thus, seven 
asymmetrical spermine derivatives were synthesised (Figure 1), purified to homogeneity, and 
then characterized by NMR and HRMS. 
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Figure 2. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the geometric 
mean fluorescence of AF647 48 h post-transfection of HeLa cells with the lipoplexes prepared 
with seven asymmetrical spermine fatty acid conjugates and symmetrical DOS. The amount of 
siEGFP-AF was kept constant at 15 pmol/well (15 nM).  
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Figure 2 shows siRNA siEGFP-AF delivery to HeLa cells as evaluated by the normalized 
geometric mean fluorescence of AF647 covalently bound to siEGFP. The amount of siRNA 
delivered (at 6 g cationic lipid/well) as measured by AF fluorescence was 30, 17, and 10 for the 
C18 fatty acid conjugates OSS, DOS, and LinOS respectively which was related inversely to 
increases in the number of C=C double bonds in the C18 fatty acids. Increasing the number of 
unsaturation sites in C24 fatty acids also decreased siRNA delivery (at 6 g cationic lipid/well, 
normalized AF fluorescence was 50 and 23 for LigOS and NOS respectively). However, 
increasing the number of unsaturation sites from one to four in EicOS and AOS respectively, 
resulted in a decrease in siRNA delivery, from 19 to 10 at 6 g cationic lipid/well (p = 0.0001), 
and from 18 to 14 at 3 g/well (p = 0.0163) for EicOS and AOS respectively. Increasing the 
chain length (EruOS, 22:1 and NOS, 24:1), while keeping the number of C=C double bonds 
constant, caused an increase in siRNA delivery compared to shorter DOS 18:1 and EicOS 20:1. 
At a cationic lipid concentration of 6 g/well, AF647 fluorescence was 17, 19, 35, and 23; and at 
3 g/well:  14, 18, 31, and 24 for DOS, EicOS, EruOS, and NOS respectively. Comparing 
saturated LigOS (with lignoceroyl chain, 24:0) and OSS (with stearoyl chain 18:0) shows that an 
increase in the chain length from C18 (OSS) to C24 (LigOS) resulted in an increase in AF647 
fluorescence from 30 to 50 respectively (p < 0.0001). 
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Figure 3. EGFP expression percentage calculated 48 h post-transfection of HeLa cells with the 
lipoplexes prepared with seven asymmetrical spermine fatty acid conjugates and symmetrical 
DOS. The amount of siEGFP-AF was kept constant at 15 pmol/well (15 nM). 
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Figure 3 shows the reduction of EGFP expression in HeLa cells 48 h post-transfection 
with lipoplexes of siEGFP and the synthesized asymmetrical fatty acid derivatives of spermine. 
C18 fatty acids with one or two unsaturation sites resulted in better reduction in EGFP 
expression. Thus, LinOS (3 g/well) gave 24% EGFP expression, DOS (6 g/well) gave 27% 
EGFP, compared to OSS (with one stearoyl 18:0) which at 3g/well gave 38% EGFP and at 6 
g/well gave 38% EGFP. The quantitative FACS data (Figures 2 and 3) are better illustrated by 
the flow cytometric graphs comprised of individual histograms (Figure 4). 
The N/P ratio is defined as the ratio of cationic lipid ammonium ions to RNA phosphate 
anions. In this case, the numerator is calculated as the number of moles of cationic lipid 
multiplied by the positive charge carried, 2.0. The value 2.0 reflects the pKa of each primary 
amine (~10.5) and the pH at which the experiments are performed (7.4) using the Henderson-
Hasselbalch equation.33 The denominator is the total number of phosphate anions which here is 
calculated from the total number of moles of siRNA multiplied by the total number of phosphates 
in ds siRNA, where a synthetic 24-mer carries 23 phosphates in each strand following 
phosphoramidite synthesis. Though the terminal sugars of uncomplexed siRNA will be 
phosphorylated in cells, lipoplexes of siRNA are prepared before this reaction, at N/P = 23.8 with 
DOS (6 g/well), N/P = 21.3 with LigOS (6 g/well), and N/P = 11.9 with LinOS (3g/well) for 
a fixed amount of siRNA (15 pmol). 
Increasing the number of unsaturation sites in C20 fatty acids resulted in better reduction 
in EGFP expression (down to 37% and 29% at 6 g/well, p < 0.0001; 52% and 34% at 3 g/well; 
p < 0.0001 for EicOS and AOS respectively). There was no significant statistical difference (p > 
0.05) between LigOS and NOS with respect to their effects on EGFP expression. Increasing the 
chain length of the fatty acid spermine derivatives from C18 to C24 while keeping number of 
C=C double bonds constant generally resulted in higher levels of EGFP across the series of 
compounds, with EGFP expression reduced to 26%, 38%, 51%, and 54% at 6 g/well of DOS, 
EicOS, EruOS, and NOS respectively. There were no differences between EicOS and EruOS at 
0.75, 1.5, and 3 g/well. Increasing the chain length from C18 to C24 in OSS and LigOS 
respectively resulted in higher levels of EGFP expression at different concentrations of lipids. At 
6 g/well, OSS resulted in EGFP expression of 38% while LigOS resulted in EGFP expression of 
56% (p < 0.0001). The efficiency of gene silencing achieved with LinOS (76%), DOS (73%), and 
OSS (62%) is comparable to that of commercially available reagents TransIT-TKO (4 L/well, 
75%) and Lipofectamine 2000 (2 L/well, 69%) used in the presence of serum (10% FCS) and in 
accordance with the manufacturers’ instructions for optimal efficiency. 
 
 
(a) Control 
(b) LigOS 
(c) LinOS 
(d) TransIT-TKO 
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(e) Lipofectamine 2000 
Figure 4. Gated FACS analysis of delivery of siEGFP-AF (15 nM, 15 pmol/well) and EGFP 
expression in HeLa cells (compared to (a) control) 48 h post-transfection with lipoplexes of (b) 
LigOS (6 µg/well) and (c) LinOS (3 µg/well). Positive controls come with the commercial 
transfection reagents (d) TransIT-TKO and (e) Lipofectamine 2000. Gate set for a healthy cell 
population (left column). The AF647 gate (red, middle column) typically shows >95% of parent-
gated cells with delivery of siEGFP-AF lipoplexes prepared with asymmetrical spermine fatty 
acid conjugates. The EGFP gate (green, right column, values measured by geometric mean 
fluorescence relative to control) shows silencing to ~20% with LinOS lipoplexes, and to ~55% 
with LigOS lipoplexes even though delivery is essentially quantitative with the latter. 
We show representative FACS results (Figure 4) with the typical graphs: forward-
scatter/side-scatter (FSC/SSC) dot graph showing the gating of the healthy cell population, the 
profile with the AF647 gate, and the profile with the EGFP gate. These data are representative in 
that they are typical and reflect a single delivery and gene silencing experiment (from 1 of 9 
wells). The conditions shown are without (as a control) and with siEGFP-AF. A qualitative 
analysis of the control cells (Figure 4a) shows a healthy and homogeneous population of EGFP 
fluorescing cells, with weak autofluorescence excluded out of the AF647 gate. Delivery of 
siEGFP-AF (15 nM, 15 pmol/well) was 6-fold greater with LigOS (6 µg/well) than with LinOS 
(3 µg/well). However, gene silencing was greater with LinOS lipoplexes than with those prepared 
with LigOS (see Figure 4 and statistics in Figure 3). Thus, these flow cytometry experiments are 
also good representatives of cationic lipids showing high delivery with low gene silencing 
(LigOS), and low delivery with good silencing (LinOS). The commercial transfection reagents 
TransIT-TKO and Lipofectamine 2000 show very high delivery, but their silencing is no better 
than that achieved with LinOS (3 µg/well) (Figure 4). Clearly, intracellular delivery and gene 
silencing are controlled by different processes and therefore functional siRNA delivery is 
affected by lipoplexes of different cationic lipids to varying extents.34 
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Figure 5. EGFP expression percentage (grey bars) calculated 48 h post-transfection of HeLa cells 
with the lipoplexes prepared with asymmetrical spermine fatty acid conjugates and siNC-AF (15 
pmol/well, 15 nM). siNC-AF fluorescence shows siRNA delivery (white bars). Cationic lipid 
amounts used were those that resulted in the best reduction in EGFP expression:  AOS (6 
g/well), EicOS (6 g/well), EruOS (6 g/well), LigOS (6 g/well), LinOS (3 g/well), NOS (6 
g/well), and OSS (6 g/well). 
 
The EGFP expression and siNC-AF delivery are shown in Figure 5. The amounts of lipids 
used were those which resulted in the best reduction in EGFP expression with respect to each 
cationic lipid (see Figure 3). The data show that while the delivery of siNC-AF for each cationic 
lipid, at the specified concentration, was with comparable efficiency to the delivery results of 
siEGFP-AF (see Figure 2), there was no significant effect (a maximum of 10% reduction) on EGFP 
expression percentage. Thus, the reduction in EGFP expression after transfection with siEGFP-AF 
lipoplexes is mainly due to sequence-specific EGFP knock-down mediated by the delivered 
siEGFP-AF, and not due to any cationic lipid-related effects, e.g. toxicity. 
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Figure 6. siEGFP-AF delivery to HeLa cells expressed as the normalized values of the geometric 
mean fluorescence of AF647 48 h post-transfection of HeLa cells with the mixtures of lipoplexes 
prepared with DOS/DLinS or DOS/DEruS at different molar ratios (total lipid weight 3 g/well). 
The amount of siEGFP-AF was kept constant at 15 pmol/well (15 nM). 
 
Mixtures of cationic lipids have been reported to enhance DNA transfection through 
synergy.35 Figure 6 shows siEGFP-AF delivery with lipoplexes of mixtures of DOS/DLinS and 
DOS/DEruS at different molar ratios of the symmetrical spermine derivatives, as well as 
comparing their siEGFP-AF delivery with the delivery by the asymmetrical LinOS and EruOS. 
DOS lipoplexes resulted in AF647 fluorescence of 14 (normalized) and DLinS resulted in 
delivery of 3. The mixtures of DOS/DLinS of molar ratio 4:1 to 1:4, resulted in AF647 
fluorescence of intermediate values between those of DOS and DLinS. When compared to 
LinOS, the siEGFP-AF delivery with the DOS/DLinS 1:1 lipoplexes resulted in lower AF647 
delivery (7 and 12 for DOS/DLinS 1:1 and LinOS respectively, p < 0.0001). The mixtures of 
DOS/DEruS of molar ratio 4:1 to 1:4, resulted in AF647 fluorescence of intermediate values 
between those of DOS (14) and DEruS (82).32 There was no statistical significant difference 
between DOS/DEruS 1:1and EruOS (33 and 31 respectively, p = 0.64). The mixtures mostly 
behave in a way which reflects the behavior of the individual components (Figure 6). DLinS 
shows the lowest uptake, consistent with our results (Figure 2) where lipids containing more C=C 
show lower uptake. DEruS has the highest uptake, also consistent with the results in Figure 2 
where the longer and more saturated lipid chains, EruOS, LigOS, and NOS show higher uptake. 
However, these mixtures of cationic lipids displayed no synergy in siEGFP-AF delivery as found 
with DNA transfection.35 
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Figure 7. EGFP expression percentage measured 48 h post-transfection of HeLa cells with the 
lipoplexes prepared with mixtures of DOS/DLinS or DOS/DEruS at different molar ratios (total 
lipid weight 3 g/well). The amount of siEGFP-AF was kept constant at 15 pmol/well (15 nM). 
 
Figure 7 shows the reduction in EGFP expression 48 h post-transfection with lipoplexes 
of mixtures of DOS/DLinS and DOS/DEruS at different molar ratios of the symmetrical 
spermine derivatives, as well as the EGFP expression resulting from transfection with lipoplexes 
of the asymmetrical LinOS and EruOS. The mixtures of DOS/DLinS of molar ratio 4:1 to 1:4, 
resulted in EGFP expression of intermediate values between those of DOS and DLinS, with 
EGFP expression increasing with the increase in DLinS content in the mixture. When compared 
to LinOS, the EGFP expression with the DOS/DLinS 1:1 lipoplexes resulted in EGFP expression 
of 34% compared to LinOS 24% (3 g/well, p < 0.0001). The mixtures of DOS/DEruS of molar 
ratio 4:1 to 1:4, resulted in EGFP expression of intermediate values between those of DOS and 
DEruS. Contrary to our results obtained with DOS/DLinS 1:1 and LinOS, EruOS resulted in 
higher EGFP expression (47%) compared to the DOS/DEruS 1:1 mixture (31%, p < 0.0001). The 
gene silencing of lipoplexes composed solely of DLinS (55%), and of DEruS (57%) show limited 
inhibition of EGFP expression (Figure 7). The mixtures mostly show gene silencing dominated 
by DOS rather than reflecting the percentage composition of the individual components. This is 
also found in the covalent binding of erucoyl and oleoyl chains in the spermine conjugate EruOS 
(gene silencing to 47%), but incorporating two different C18 acyl chains in the asymmetrical 
LinOS, linoleoyl and oleoyl, affords the best gene silencing (24%). 
 
 
(a) (b) 
(c) (d) 
Figure 8. Confocal photomicrographs of HeLa cells before and after transfection of siEGFP-AF 
with LinOS (3 µg/well). The cell membrane is stained with Alexa Fluor 555 (blue). Representative 
pictures are shown. (a) Untransfected HeLa cells stably expressing EGFP (green). (b) Detection of 
siEGFP-AF (red dots), only 4 h post-transfection. (c) EGFP expression with the green channel on as 
in (a) and (b), monitored 48 h post-transfection. EGFP expression is largely reduced (cf FACS data, 
Figure 4b). (d) As (b) with the FACS green and blue channels turned off for clarity. 
Figure 8a shows non-transfected (control) HeLa cells expressing EGFP (green) within the cell 
membrane (blue). Figures 8b and 8d show HeLa cells only 4 h post-transfection with lipoplexes 
of siEGFP-AF and LinOS (3 µg/well). Figure 8b shows that while siEGFP-AF (red) has been 
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delivered, EGFP is still strongly expressed throughout the cell. In Figure 8d, the green channel 
was turned-off to better visualize the red colour representing siEGFP-conjugated dye AF647 
(siEGFP-AF). Note that the lower cell shows higher uptake compared to the upper cell. In Figure 
8c, EGFP (green) is barely detectable at 48 h post-transfection, compared to the control 
untransfected cells shown in Figure 8a. Scattered red dots indicate that siEGFP-AF is still present 
48 h post-transfection. Taken together, the photomicrographs shown in Figure 8 demonstrate the 
apparent efficient uptake of lipoplexes of siEGFP-AF and LinOS (3 µg/well) and the subsequent 
very dramatic reduction (knock-down) of EGFP expression, at least up to 48 h post-transfection. 
We note that LinOS (at 3 and even at 6 µg/well, Figure 2) shows the lowest siRNA delivery, but 
with siEGFP-AF held constant at 15 pmol/well (15 nM), LinOS (3 µg/well) forms the most 
efficient lipoplexes for gene silencing (Figure 3) even though this high efficacy is not reflected in 
high delivery. 
 
 
 
Figure 9. A Z-stack confocal photomicrograph gallery of photomicrographs representing 12 Z-
sections in HeLa cells transfected with lipoplexes of LinOS (3 g/well) and siEGFP-AF (15 
pmol). EGFP fluorescence (green), cell membrane stained with WGA-Alexa Fluor® 555 (blue), 
and Alexa Fluor® 647 (red) representing tagged siRNA delivery. 
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In order to further highlight the intracellular detection of siEGFP-AF monitored 48 h 
post-transfection (shown above in Figure 8b and 8d as red dots), where (Figure 8c) there is 
almost no detectable EGFP expression (with the green channel turned on), a Z-stack gallery was 
recorded through a monolayer of transfected HeLa cells (Figure 9). Z-Stacks are a series of 
successive optical sections acquired at different positions along the Z-axis (in 1.0 m slices). The 
first optical section was taken slightly lower than the surface of the cells attached to the cover 
slip, then the sections were recorded while slicing through to the opposite surface. Figure 9 
shows that majority of the red colour (representing siRNA delivery) is present inside the cell, the 
blue colour representing cell membrane is only present at the perimeter of the cells, and 
occasionally the red colour is present simultaneously with the blue colour indicating Alexa 
Fluor® 647 (red) (bound to siRNA) within the membrane. As we slice along the Z-axis, there is 
no blue colour in the middle of the cells where there is red. Minko and co-workers have recently 
reported the use of Z-stack photomicrographs to determine the orientation of the delivered 
siRNA, where a NuLight DY-547 fluorophore tagged siRNA was delivered to A2780 human 
ovarian cancer cells by surface neutral, but internally cationic polyamidoamine dendrimers.36  
DLS was used to measure the particle sizes (Table 1) of the lipoplexes prepared at the 
cationic lipid/siRNA ratio that resulted in the largest reduction in EGFP expression. The size 
range is 145-292 nm (from OSS to AOS) which is in agreement with the size range of lipoplexes 
previously reported to transfect successfully in cell culture.37 The particle size could determine 
the main route of cellular entry, with lipoplexes <300 nm likely to enter via clathrin-mediated 
endocytosis, and lipoplexes >500 nm entering cells via caveoli-mediated endocytosis.37, 38 
However, the entry route for functional siRNA delivery might be by fusion with the cell 
membrane rather than via an endocytic pathway, as demonstrated using selective inhibitors.34 The 
ζ-potentials of the prepared lipoplexes (Table 1) are all positive (40-59 mV). Such a net positive 
charge on the lipoplex surface is important in promoting lipoplex-lipoplex repulsion, thus 
preventing aggregation. The RiboGreen siRNA binding assay results (Table 1) show that the 
asymmetrical spermine conjugates are able to bind siRNA almost completely, with the 
fluorescence of RiboGreen dye reduced to values of 1-5% of the control. The two free terminal 
primary amine groups of the acylated spermine conjugates are practically fully protonated at 
physiological pH 7.4.  
 
Table 1. Particle diameter, ζ-potential, and siRNA binding assay of fatty acid amides of spermine 
measured at the cationic lipid/siRNA ratios that showed best knock-down of EGFP (all shown as 
Mean ± S.D.). 
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cationic 
lipid 
diameter 
(nm) 
ζ-potential 
(mV) 
% fluorescence 
of RiboGreen 
AOS 292 ± 36 49 ± 1 4 ± 1 
EicOS 273 ± 11 55 ± 2 2 ± 1 
EruOS 286 ± 29 51 ± 2 2 ± 1 
LigOS 241 ± 26 59 ± 6 1 ± 1 
LinOS 225 ± 20 53 ± 3 4 ± 1 
NOS 291 ± 26 40 ± 4 1 ± 1 
OSS 145 ± 7 56 ± 2 5 ± 1 
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Figure 10. Cell viability (alamarBlue assay) 48 h post-transfection of HeLa cells with the 
lipoplexes prepared with spermine fatty acid conjugates, using 6,500 cells/well, and transfection 
with lipoplexes was 24 h after seeding the cells. The amount of siNC was kept constant (1.5 
pmol/well, 15 nM) and amounts of lipids were adjusted accordingly to the same cationic 
lipid/siRNA ratio that resulted in the best reduction in EGFP expression:  AOS (0.6 g/well), 
EicOS (0.6 g/well), EruOS (0.6 g/well), LigOS (0.6 g/well), LinOS (0.3 g/well), NOS (0.6 
g/well), and OSS (0.6 g/well); compared with DOS (0.6 g/well), Lipofectamine 2000 (Lipof, 
0.2 L/well), and TransIT-TKO (0.4 L/well). 
 
For pragmatic cell viability assays, we downscaled from the transfection conditions in 
24-well (1 mL) format to 96-well (0.1 mL) format, after establishing that 4,000-6,500 cells/well 
was an optimal range for reproducible results and in order to avoid problems of overconfluency. 
To keep the ratios and concentrations the same, the weight of cationic lipid and the amount of 
siRNA were each reduced to one tenth of their original values. The two cell viability assay 
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conditions we employed reflect the experimental conditions used in gene silencing (0.5 h 
between seeding and transfection) and in confocal microscopy where the time after seeding was 
24 h to allow the cells to attach well and distribute evenly on the cover slips. In comparison, 
when using FACS to quantify gene silencing, there was no requirement for a long time between 
seeding and transfection as there was no requirement for stronger attachment to cover slips.  
The weight of lipid chosen in Figure 10 is based on the ratio of lipid/siEGFP-AF that 
resulted in the best reduction in EGFP expression as seen in Figure 3. The percentage cell 
viabilities, shown in Figure 10, indicate that transfection of HeLa cells with lipoplexes of siRNA 
and the synthesized asymmetrical spermine derivatives resulted in cell viabilities above 74%, 
with LinOS (0.3 g/well) resulting in 88% viability and DOS 85% viability (0.6 g/well) which 
is comparable to TransIT-TKO (81%) and better than Lipofectamine 2000 (62%).  
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Figure 11. Cell viability (alamarBlue assay) 48 h post-transfection of HeLa cells with the 
lipoplexes prepared with spermine cationic lipids using 4,000 cells/well and transfection 0.5 h 
after seeding. The amount of siRNA (siNC) was kept constant at 1.5 pmol/well (15 nM) and 
amounts of cationic lipids were adjusted accordingly. 
 
Figure 11 shows the cell viabilities after transfection of HeLa cells using a lower number 
of cells (4,000 cell/well in 96-well format) and carrying out the transfection within 0.5 h of 
seeding the cells, aiming to make the transfection conditions harsher for the cells, such that 
individual differences between each of the cationic lipids at their different concentrations can be 
compared. Figure 11 also shows that increasing the amounts of lipids per well from 0.075 to 0.6 
g resulted in a decrease in cell viability. The viabilities resulting from transfection with 
lipoplexes of LinOS and DOS (the cationic lipids that showed the best reduction in EGFP 
expression as shown in Figure 3) were reduced from 96% to 84% to 65% to 52% (LinOS) and 
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from 95% to 77% to 50% to 33% (DOS) at 0.075, 0.15, 0.3, and 0.6 g/well respectively. The 
lowest cell viabilities were due to transfection with EruOS lipoplexes (from 94%, 53%, 26%, and 
14% at 0.075, 0.15, 0.3, and 0.6 g/well of EruOS respectively). 
 
DISCUSSION 
 
We have designed, synthesized, purified, and tested in a variety of physico-chemical and 
cell biological assays asymmetrical lipopolyamines based on spermine, possessing two primary 
amines. These are novel divalent cationic lipids. Assessment using both flow cytometry and 
fluorescence microscopy in human HeLa cells, measuring both delivery of the fluorescently 
tagged siRNA and silencing the EGFP signal in a stably transfected cell line, allowed 
quantitation of the differences between asymmetrical cationic lipids, selected mixtures of their 
symmetrical counterparts, and comparison with commercially available non-viral delivery agents. 
In this study, we report the design of a series of novel spermine based cationic lipids, making 
variations in the hydrophobic domain by changing the type of fatty acids conjugated to the parent 
spermine molecule. Koynova et al. reported the impact of changing the hydrophobic moiety of 
cationic lipids on DNA transfection efficiency.39 Data from 20 cationic phosphatidylcholine (PC) 
derivatives show that the chain saturation state and chain length, representing hydrophobic 
volume and cationic lipid hydrophilic-lipophilic balance (HLB), are major factors that determine 
DNA transfection efficiency, with variations in efficiency by more than two orders of magnitude, 
and also that lipid chain asymmetry has a strong impact on DNA transfection efficiency while 
keeping the HLB of cationic lipids constant.39  
The human cervical epithelial adenocarcinoma HeLa cell line is a well-described model 
of cancer cells and hence is a relevant tool for studies on siRNA- or shRNA-mediated silencing. 
In this paper, as a first step towards assessing the efficiency of our compounds at delivering 
siRNA into cells, we chose HeLa cells stably expressing a reporter gene coding for the 
fluorescent protein EGFP, under the control of a constitutive promoter, a strategy used in a 
number of other studies.28, 29, 40, 41 The advantages of using a stably transfected cell line are that 
this simple experimental system allows expression of the protein, translated from the reporter 
gene at a steady-state level, and a fast assessment on the effect of EGFP-directed siRNA delivery 
by flow cytometry (FACS) and fluorescence microscopy. Stable transfection of the target gene of 
interest (with expression vector pEGFP-C1 pDNA in this study) only requires the cells to be kept 
under selective pressure with an antibiotic (aminoglycoside G418 in our system) to prevent loss 
of pDNA during cell cultivation. The loss of genome-integrated exogenous pDNA with cell 
division during in vitro cultivation is a known phenomenon and it can only be reduced/prevented 
by keeping the cells under some pressure, with a non-toxic antibiotic (G418) concentration. 
Furthermore, as in our experimental system cell populations studied are asynchronous, any 
potential effects of the cell cycle on the reporter gene are averaged and the related protein levels 
will vary with the efficiency in silencing of the delivered siRNA. 
Whilst these studies are in HeLa cells stably expressing EGFP to test the efficiency of the 
lipoplexes of asymmetrical lipopolyamines to deliver siRNA and then achieve gene silencing, 
they are comparable with recently reported siRNA delivery in C6 glioma cells stably expressing 
GFP,40 and antisense studies in human cervical cancer HeLa705 cells containing an aberrant 
luciferase gene.41 Likewise, this in vitro evaluation strategy has been used in HeLa-EGFP cells28 
and HeLa expressing either EGFP or luciferase.29 It is likely that any correlation with in vivo 
performance will follow results obtained at high serum levels.42 siRNA for intravenous 
administration must be stable in full (human) serum. Our use of 10% FCS is a step towards this. 
Non-viral DNA vectors prepared from cationic lipids that are composed of asymmetrical 
fatty acid chains have been reported to have higher in vitro43 and/or in vivo44 efficiencies in 
comparison with their symmetrical counterparts. Several hypotheses have been put forward to 
explain the superior DNA transfection efficiency of asymmetrical cationic lipids. Ali et al. 
reported that fatty chain asymmetry in membrane lipids affects the physical environment of 
liquid-crystalline bilayers.21 PCs showing a relatively large difference in chain length (larger 
asymmetry, e.g. 18:0/8:0 or 18:0/10:0 PCs) resulted in 20-25% greater in-plane elasticity 
compared to PCs with less asymmetry (16:0-18:1 PCs) and to symmetrical PCs (di18:1). Heyes 
et al.43 suggested that the difference in length between the fatty chains allows for better 
overlapping within biological lipid bilayers following the work of Balasubramaniam et al. who 
proposed that asymmetrical lipids have increased fusogenicity.45 
The effect on DNA transfection efficiency of changing the saturation state in one chain 
was reported by Koynova et al.46 Comparing two asymmetric cationic phospholipid derivatives, 
oleoyldecanoylethyl-PC (C18:1/C10:0) and stearoyldecanoylethyl-PC (C18:0/C10:0), resulted in 
the former compound with the oleoyl chain showing 50-fold more DNA transfection efficiency 
than the latter with the saturated stearoyl chain. This DNA transfection efficiency result was 
attributed to the enhanced fusibility of the (C18:1/C10:0) lipid with cellular lipid membranes, and 
to the facilitated release of DNA due to phase reorganization, lamellar to non-lamellar transitions, 
and extensive phase coexistence as a result of lipid mixing at physiological temperatures.46 The 
processes of siRNA lipoplex delivery (uptake) and gene silencing are different from each other 
and different from DNA transfection. Our gene silencing of EGFP expression results show that 
siRNA lipoplexes self-assembled with lipopolyamines possessing one or two centres of 
unsaturation in the acyl chains (e.g. DOS, LinOS) lead to more gene silencing compared to 
similar lipoplexes containing saturated chains of the same length (e.g. stearoyl in OSS). siRNA 
uptake was highest with the symmetrical DEruS.32 
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Synergistic effects of mixtures of cationic lipids have also been reported to enhance 
DNA transfection. However, mixtures of N-[1-(2,3-dimyristoyloxy)propyl]-N,N,N­
trimethylammonium (DMTAP) and N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium 
(DOTAP) show intermediate values of DNA transfection efficiencies compared to using pure 
parent lipids as a linear function of lipid mixture composition.35 Enhanced DNA transfection 
following the use of lipid mixtures is possibly due to the change of the hydrophobic volumes of 
the lipids, related to the average hydrophobicity of the mixture and/or the heterogeneous 
distribution of the hydrophobic domains of the mixtures. Also, the presence of more than one 
lipid results in an increase in the degrees of freedom of lipoplex-membrane interactions 
eventually leading to better fusogenicity.35 siRNA lipoplex formation and delivery do not 
necessarily follow the same constraints as those of DNA lipoplexes due to the significant 
structural differences between DNA and siRNA regarding molecular weight and rigidity. Thus, 
the aforementioned hypotheses regarding DNA self-assembled lipoplexes should be applied 
cautiously to siRNA lipoplexes. 
The use of mixtures e.g. DOS/DLinS and DOS/DEruS, at different molar ratios of the 
symmetrical spermine derivatives, afforded similar or lower siEGFP-AF delivery in comparison 
with their related asymmetrical cationic lipids (LinOS and EruOS). Reduction in EGFP expression 
48 h after transfection with lipoplexes prepared from mixtures of these symmetrical cationic lipids 
was poorer than that achieved with the related asymmetrical cationic lipid LinOS, but better than 
that achieved with EruOS. In the alamarBlue assay, cell viability of LinOS lipoplexes was 88%. 
LinOS is an excellent, efficient, non-toxic cationic lipid in HeLa cells, comparable or superior to 
commercially available reagents TransIT-TKO and Lipofectamine 2000. 
The amount of siEGFP-AF delivered to HeLa cells was lower with more C=C double 
bonds in the lipid moiety. Increasing the chain length, while keeping the number of C=C 
constant, caused an increase in siRNA delivery. C18 fatty acids with one or two unsaturation 
sites resulted in better reduction in EGFP expression and increasing the number of unsaturation 
sites in C20 fatty acids also resulted in better reduction in EGFP expression in HeLa cells 48 h 
post-transfection. Increasing the chain length of the fatty acid spermine derivatives from C18 to 
C24 while keeping number of C=C double bonds constant was generally less efficient for gene 
silencing. We have shown that reduction in EGFP expression after transfection with siEGFP-AF 
lipoplexes is due to sequence-specific EGFP knock-down mediated by the delivered siEGFP-AF, 
and not due to any cationic lipid-related effects, e.g. toxicity. We conclude that the effects of 
different hydrophobic domains are not equal on intracellular delivery of siRNA and on gene 
silencing by siRNA. Control of these processes can be achieved with different N4,N9-diacyl 
spermines where gene silencing is efficiently demonstrated using lipoplexes of LinOS. 
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